Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Dual Checkpoint Inhibition Leads to Higher Response Rates vs Anti–PD-1 Therapy in High-Risk Resectable Melanoma

April 9th 2024

Ipilimumab plus nivolumab increased response rates vs anti–PD-1 monotherapy, but also increased grade 3 or 4 immune-related adverse effects, in melanoma.

Dr Migden on RP1 in Advanced Cutaneous Malignancies After Solid Organ Transplant

April 8th 2024

Michael R. Migden, MD, discusses efficacy data for RP1 in advanced non-melanoma skin cancer after prior solid organ transplant.

Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy

March 18th 2024

China’s NMPA has approved tunlametinib for the treatment of patients with NRAS-mutated advanced melanoma after prior anti–PD-1/PD-L1 therapy.

UV1 Vaccination Plus Nivolumab/Ipilimumab Falls Short in Metastatic Melanoma

March 7th 2024

The addition of UV1 to nivolumab/ipilimumab failed to improve PFS in the frontline treatment of unresectable or metastatic melanoma.

Dr Olson on the FDA Approval of Lifileucel for Advanced Melanoma

March 5th 2024

Daniel Olson, MD, discusses the FDA approval of lifileucel for patients with advanced melanoma whose disease has been previously treated.

Dr Gross on the Safety of Neoadjuvant Cemiplimab in Stage II/IV CSCC

March 5th 2024

Neil D. Gross, MD, FACS, discusses key safety data from a phase 2 study of neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

FDA Approval Highlights: OncLive’s February Recap

February 29th 2024

In case you missed it, below is a recap of all drugs that have been approved by the FDA in February 2024.

Addition of Lifileucel to Advanced Melanoma Arsenal Marks Milestone for TIL Therapy in Solid Tumor Management

February 27th 2024

Daniel Olson, MD, discusses the significance of the FDA approval of lifileucel for patients with advanced melanoma.

Current Standard of Care for Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma

February 23rd 2024

Nikhil I. Khushalani, MD, of Moffitt Cancer Center, discusses current therapeutic options for patients with locally advanced cutaneous squamous cell carcinoma.

Diagnosis and Prognosis of Locally Advanced Cutaneous Squamous Cell Carcinoma

February 23rd 2024

Nikhil I. Khushalani, MD, of Moffitt Cancer Center, discusses the diagnosis and prognosis of patients with locally advanced cutaneous squamous cell carcinoma.

Dr Gross on the Background of Investigating Neoadjuvant Cemiplimab in CSCC

February 23rd 2024

Neil D. Gross, MD, FACS, discusses a phase 2 study evaluating neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

Dr Kluger on the FDA Approval of Lifileucel in Advanced Melanoma

February 16th 2024

Harriet Kluger, MD, discusses the FDA approval of the tumor infiltrating lymphocyte therapy lifileucel for patients with advanced melanoma.

FDA Approves Lifileucel for Unresectable or Metastatic Melanoma

February 16th 2024

The FDA has approved lifileucel suspension (Amtagvi) for adult patients with unresectable or metastatic melanoma following prior treatment with a PD-1 inhibitor, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor.

FDA Approves AI-Powered Detection Device for Skin Cancers

February 16th 2024

The FDA has granted clearance for the first real-time, non-invasive skin cancer evaluation system .

BLA Resubmitted to FDA for Denileukin Diftitox in Relapsed/Refractory Cutaneous T-cell Lymphoma

February 14th 2024

The BLA seeking the approval of denileukin diftitox in patients with relapsed/refractory cutaneous T-cell lymphoma was resubmitted to the FDA.

Extending the Frontiers of Checkpoint Inhibition in Merkel Cell Carcinoma

February 14th 2024

In the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.

Dr Nathan on the Significance of Tebentafusp in HLA-A*02:01+ Uveal Melanoma

February 13th 2024

Paul D. Nathan, MBBS, PhD, FRCP, discusses the clinical significance of updated data on tebentafusp in metastatic uveal melanoma.

Long-Term CheckMate 238 Data Support Adjuvant Nivolumab Vs Ipilimumab in Resected Melanoma

February 13th 2024

Adjuvant nivolumab significantly improved relapse-free survival vs ipilimumab in resected stage III/IV melanoma, according to 7-year minimum follow-up.

PRAME Shows Promise as a Treatment Avenue in Melanoma, Other Solid Tumors

February 12th 2024

Preferentially expressed antigen in melanoma has emerged as a target for treatment development in multiple solid tumors.

Dr Weber on the Background of the KEYNOTE-942 Trial in High-Risk Melanoma

February 8th 2024

Jeffrey S. Weber, MD, PhD, discusses the background for the KEYNOTE-942 trial, which was conducted in resected high-risk melanoma.